Anti-Met (c-Met) (phospho Y1234 + Y1235) antibody, prediluted (ab82094)

Overview

  • Product nameAnti-Met (c-Met) (phospho Y1234 + Y1235) antibody, predilutedSee all Met (c-Met) primary antibodies ...
  • Description
    Rabbit polyclonal to Met (c-Met) (phospho Y1234 + Y1235), prediluted
  • SpecificityThis antibody is specific for Met (c-Met), only when phosphorylated at tyrosine 1235 and 1235.
  • Tested applicationsIHC-Pmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to the region of Met (c-Met) that contains phosphorylated tyrosine 1234/1235.

  • Positive control
    • Breast carcinoma tissue

Properties

Applications

Our Abpromise guarantee covers the use of ab82094 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
IHC-P
  • Application notesIHC-P: ready to use.


    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • FunctionReceptor for hepatocyte growth factor and scatter factor. Has a tyrosine-protein kinase activity. Functions in cell proliferation, scattering, morphogenesis and survival.
    • Involvement in diseaseNote=Activation of MET after rearrangement with the TPR gene produces an oncogenic protein.
      Note=Defects in MET may be associated with gastric cancer.
      Defects in MET are a cause of hepatocellular carcinoma (HCC) [MIM:114550].
      Defects in MET are a cause of renal cell carcinoma papillary (RCCP) [MIM:605074]. It is a subtype of renal cell carcinoma tending to show a tubulo-papillary architecture formed by numerous, irregular, finger-like projections of connective tissue. Renal cell carcinoma is a heterogeneous group of sporadic or hereditary carcinoma derived from cells of the proximal renal tubular epithelium. It is subclassified into common renal cell carcinoma (clear cell, non-papillary carcinoma), papillary renal cell carcinoma, chromophobe renal cell carcinoma, collecting duct carcinoma with medullary carcinoma of the kidney, and unclassified renal cell carcinoma.
      Note=A common allele in the promoter region of the MET shows genetic association with susceptibility to autism in some families. Functional assays indicate a decrease in MET promoter activity and altered binding of specific transcription factor complexes.
      Note=MET activating mutations may be involved in the development of a highly malignant, metastatic syndrome known as cancer of unknown primary origin (CUP) or primary occult malignancy. Systemic neoplastic spread is generally a late event in cancer progression. However, in some instances, distant dissemination arises at a very early stage, so that metastases reach clinical relevance before primary lesions. Sometimes, the primary lesions cannot be identified in spite of the progresses in the diagnosis of malignancies.
    • Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family.
      Contains 3 IPT/TIG domains.
      Contains 1 protein kinase domain.
      Contains 1 Sema domain.
    • DomainThe kinase domain is involved in SPSB1 binding.
    • Post-translational
      modifications
      Dephosphorylated by PTPRJ at Tyr-1349 and Tyr-1365.
    • Cellular localizationMembrane.
    • Information by UniProt
    • Database links
    • Alternative names
      • AUTS9 antibody
      • c met antibody
      • D249 antibody
      • Hepatocyte growth factor receptor antibody
      • HGF antibody
      • HGF receptor antibody
      • HGF/SF receptor antibody
      • HGFR antibody
      • MET antibody
      • Met proto oncogene tyrosine kinase antibody
      • Met proto-oncogene (hepatocyte growth factor receptor) antibody
      • Met proto-oncogene antibody
      • Met protooncogene antibody
      • MET_HUMAN antibody
      • Oncogene MET antibody
      • Par4 antibody
      • Proto-oncogene c-Met antibody
      • RCCP2 antibody
      • Scatter factor receptor antibody
      • SF receptor antibody
      • Tyrosine-protein kinase Met antibody
      see all

    Anti-Met (c-Met) (phospho Y1234 + Y1235) antibody, prediluted images

    • Immunohistochemical analysis of human breast carcinoma tissue stained with ab82094.

    References for Anti-Met (c-Met) (phospho Y1234 + Y1235) antibody, prediluted (ab82094)

    ab82094 has not yet been referenced specifically in any publications.

    Product Wall

    Thank you for contacting us. Your credit note ID is xxxx. I am sorry that this antibody did not perform as stated on the datasheet. I have asked our accounting department to issue a credit note for you, which can be redeemed against the invoice o...

    Read More

    Thank you for confirming these details and for your cooperation. The details provided enable us to closely monitor the quality of our products. I am sorry this product did not perform as stated on the datasheet and for the inconvenience this has cau...

    Read More

    Thank you for your reply.

    Could you please confirm the Abcam order confirmation number or the PO and date of purchase. In order to process a free of charge replacement I will need this information.

    I look forward to hearing f...

    Read More

    I am sorry that I was unavailable when you called but am glad to hear from you. We would not suggest using 5% BSA instead of the protein block included with the kit. These blocking solutions are formulated to give the best result with the kit. I...

    Read More

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"